Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
admin A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreResearch/Development
Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreGSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine…
Read MoreSteve Case says the next five years will be about ‘the internet meeting the real world’
When MarketWatch first started delivering financial news and data exclusively online in 1997, about half…
Read MoreHow Lehman and the iPhone reshaped financial markets
We are marking MarketWatch’s 25th anniversary by looking at the 25 biggest financial market events…
Read MoreHe saved credit cards, and now he’s inspiring crypto enthusiasts
As cryptocurrency enthusiasts look to build out the future of money, some are looking back…
Read MoreWhy aren’t new drugs that can help you lose weight more widely used?
A pair of new drugs offer something many Americans desperately want: a way to lose…
Read MoreGetting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive…
Read MoreEisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read More